Mounjaro and spots on your face: what the evidence says

Is tirzepatide itself causing your spots?

The short answer is: probably not directly. The NHS patient information page for tirzepatide lists the most common side effects as gastrointestinal (nausea, vomiting, diarrhoea, indigestion) along with injection-site reactions, headache, dizziness and fatigue. Facial spots don't appear on that list. The UK SmPC for Mounjaro, published on the Electronic Medicines Compendium, similarly does not identify acne or facial spots as a known adverse effect. That matters, because the SmPC is compiled from clinical trial data involving thousands of adults in the SURMOUNT programme.

What that doesn't mean is that your skin experience isn't real. It means the drug's direct mechanism isn't the obvious culprit. Tirzepatide works as a dual GIP and GLP-1 receptor agonist, slowing gastric emptying and reducing appetite. None of those pathways have an established direct route to comedone formation on the face. If you'd like a broader picture of how the medicine works, our tirzepatide overview covers the mechanism in plain language.

A question our prescribers hear most weeks: "Could my pen be causing this?" The honest clinical answer is that the pen is rarely to blame for what's happening on your face specifically, but the changes that come with weight loss and reduced food intake very often are.

The indirect causes that are much more likely

Starting Mounjaro usually means eating significantly less, switching food choices and losing weight at a pace the body hasn't experienced before. Each of those shifts can do something to your skin.

Rapid weight loss changes hormone levels, including androgens, which are closely linked to sebum production and acne. Even modest fluctuations can push skin into a reactive phase, particularly around the jawline, chin and forehead. If you are also using hormonal contraception, it is worth knowing that tirzepatide can slow gastric emptying, and for the first four weeks of treatment and for four weeks after each dose increase, additional non-oral contraception is recommended alongside the pill, this is covered in detail on the Mounjaro and face changes page. Any shift in hormonal contraception, or uncertainty about absorption, could theoretically affect hormone-driven skin.

Dehydration is another factor. GI side effects, particularly early in treatment, can mean people drink less or lose more fluid than they realise. Dehydrated skin can paradoxically overproduce oil as a compensatory response. Stress and disrupted sleep (both common when starting a new treatment) round out the picture. None of these require the drug to be acting directly on the skin at all.

For context on the full range of skin and physical changes some people notice on tirzepatide, the can Mounjaro cause spots page explores the evidence in more depth.

When to seek medical advice and when to monitor

Most mild breakouts that appear in the first weeks of treatment settle as the body adapts. The calculus changes if:

The spots are accompanied by swelling, hives, difficulty breathing or widespread rash, those could signal an allergic reaction and need same-day medical assessment. If the reaction is severe, call 999 or go to A&E.

Spots are appearing at or near your injection site rather than on your face, that's a different picture, a recognised injection-site reaction, and worth mentioning at your next prescriber review.

You are also experiencing severe, persistent abdominal pain that reaches your back, with or without vomiting, that is the warning sign the MHRA highlighted in its January 2026 Drug Safety Update on GLP-1 medicines and acute pancreatitis, and it needs urgent attention regardless of what your skin is doing.

For anything that doesn't fit the urgent categories above, the practical step is to note when the spots appeared relative to your dose schedule, whether they worsen after each injection, and whether your hydration and sleep have changed. That information is genuinely useful for your prescriber when they review your treatment. Suspected side effects of any kind can also be reported directly to the MHRA via the Yellow Card scheme, patients as well as clinicians can submit reports, and doing so helps build the real-world evidence base for newer medicines like Mounjaro.

The decision you're actually facing

Facial spots are uncomfortable and, for some people, distressing enough to make them question whether to continue treatment. That's a proportionate reaction. The decision tree here is relatively straightforward, though.

If spots are mild and you are losing weight without other concerning symptoms, monitoring and adjusting hydration and diet is a reasonable first step. Many people find skin settles within four to eight weeks. If they are persistent, worsening, or affecting your confidence significantly, a dermatologist review alongside your prescriber review is worth requesting, the two things can happen in parallel without stopping treatment.

If you are considering stopping Mounjaro over skin concerns alone, it is worth discussing that specifically with your prescriber rather than doing so unilaterally. The spots may have a manageable cause; stopping means restarting a dose-escalation schedule if you return. That's not a reason to push through something genuinely distressing, but it is information worth having.

You can read more about the broader evidence on whether Mounjaro gives you spots, or explore the full picture of skin and physical changes some patients notice on our Mounjaro spots page. If you are curious about what extreme weight loss on tirzepatide looks like in trial data, the extreme weight loss on Mounjaro page covers that evidence clearly.

If you are thinking about starting treatment and want your full health picture reviewed, start your free consultation and a GPhC-registered prescriber will go through everything with you the same day.